We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Private Spanish Healthcare Acquires Inova Diagnostics

By HospiMedica staff writers
Posted on 29 Jan 2008
Werfen Group (Barcelona, Spain), a privately held healthcare corporation, has reached a definitive agreement to complete the acquisition of Inova Diagnostics, Inc. More...
(San Diego, CA, USA), a medical diagnostics firm. The transaction is expected to close in the first quarter of 2008, subject to required government approvals. Financial terms have not been disclosed.

Inova develops and manufactures in vitro diagnostic (IVD) tests for autoimmune diseases. "For most of Inova's history, autoimmune diseases were perceived as a relatively small and esoteric segment of the ‘in vitro' diagnostic market. Recent scientific discoveries however are finding autoimmune characteristics in many of the more common diseases such as arthritis, liver disease, atherosclerosis, celiac disease, and diabetes,” said Dr. Walter Binder, Inova's chief scientist.

Dr. Binder added, "Some of these diseases can affect up to one percent or more of the general population. As Inova develops new tests based on these discoveries, we realize we require greater financial, marketing, and distribution resources to bring these new assays to market. The Werfen Group brings the necessary resources to allow Inova to continue to aggressively pursue the many growth opportunities for our business segment throughout the world.”

Jose Luis Martin, spokesperson for Werfen, stated, "Inova's research pipeline and scientific expertise is complementary to Werfen's ‘in vitro' test and instrumentation product line. We are excited by the growth prospects for this segment of the medical diagnostic industry and we are ready to assist Inova in realizing their growth plans. We expect to keep Inova's research, manufacturing, and administrative operations in San Diego and expand them as necessary in that area.”


Related Links:
Werfen Group
Inova Diagnostics

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Manual Pipetting Aid
Pipette Controllers macro
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.